Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli

Background: AmpC beta lactamases are cephalosporinases that confer resistance to a wide range of beta lactam drugs thereby causing serious therapeautic problem. As there are no CLSI guidelines for detection of AmpC mediated resistance in Gram negative clinical isolates and it may pose a problem due...

Full description

Bibliographic Details
Main Authors: Deepika Handa, Anita Pandey, Ashish Kumar Asthana, Ashutosh Rawat, Seemant Handa, Bhaskar Thakuria
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Indian Journal of Pathology and Microbiology
Subjects:
Online Access:http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=2;spage=135;epage=138;aulast=Handa
_version_ 1819176012355731456
author Deepika Handa
Anita Pandey
Ashish Kumar Asthana
Ashutosh Rawat
Seemant Handa
Bhaskar Thakuria
author_facet Deepika Handa
Anita Pandey
Ashish Kumar Asthana
Ashutosh Rawat
Seemant Handa
Bhaskar Thakuria
author_sort Deepika Handa
collection DOAJ
description Background: AmpC beta lactamases are cephalosporinases that confer resistance to a wide range of beta lactam drugs thereby causing serious therapeautic problem. As there are no CLSI guidelines for detection of AmpC mediated resistance in Gram negative clinical isolates and it may pose a problem due to misleading results, especially so in phenotypic tests. Although cefoxitin resistance is used as a screening test, it does not reliably indicate AmpC production. Materials and Methods: We planned a study to determine the occurrence of AmpC beta lactamase in hospital and community, clinical isolates of Escherichia coli and simultaneously evaluate different phenotypic methods for detection of AmpC beta lactamases. Results: It was observed that 82.76% isolates were ESBL positive and 59% were cefoxitin screen positive. Using phenotypic confirmatory tests the occurrence of Amp C beta lactamases was found to be 40% and 39% by inhibitor based method using boronic acid (IBM) and modified three dimensional test (M3D) respectively. Conclusion: Both the test showed concordant result. Co-production was observed in 84.62% isolates Screening of ESBL and Amp C can be done in routine clinical microbiology laboratory using aztreonam and IBM respectively as it is a simple, rapid and technically less demanding procedure which can be used in all clinical laboratories.
first_indexed 2024-12-22T21:03:59Z
format Article
id doaj.art-5194329a750d4440985e9bf4782561e0
institution Directory Open Access Journal
issn 0377-4929
language English
last_indexed 2024-12-22T21:03:59Z
publishDate 2013-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Indian Journal of Pathology and Microbiology
spelling doaj.art-5194329a750d4440985e9bf4782561e02022-12-21T18:12:44ZengWolters Kluwer Medknow PublicationsIndian Journal of Pathology and Microbiology0377-49292013-01-0156213513810.4103/0377-4929.118686Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coliDeepika HandaAnita PandeyAshish Kumar AsthanaAshutosh RawatSeemant HandaBhaskar ThakuriaBackground: AmpC beta lactamases are cephalosporinases that confer resistance to a wide range of beta lactam drugs thereby causing serious therapeautic problem. As there are no CLSI guidelines for detection of AmpC mediated resistance in Gram negative clinical isolates and it may pose a problem due to misleading results, especially so in phenotypic tests. Although cefoxitin resistance is used as a screening test, it does not reliably indicate AmpC production. Materials and Methods: We planned a study to determine the occurrence of AmpC beta lactamase in hospital and community, clinical isolates of Escherichia coli and simultaneously evaluate different phenotypic methods for detection of AmpC beta lactamases. Results: It was observed that 82.76% isolates were ESBL positive and 59% were cefoxitin screen positive. Using phenotypic confirmatory tests the occurrence of Amp C beta lactamases was found to be 40% and 39% by inhibitor based method using boronic acid (IBM) and modified three dimensional test (M3D) respectively. Conclusion: Both the test showed concordant result. Co-production was observed in 84.62% isolates Screening of ESBL and Amp C can be done in routine clinical microbiology laboratory using aztreonam and IBM respectively as it is a simple, rapid and technically less demanding procedure which can be used in all clinical laboratories.http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=2;spage=135;epage=138;aulast=HandaAmpC beta-lactamasesextended spectrum beta-lactamasesinhibitor based testmodified 3D test
spellingShingle Deepika Handa
Anita Pandey
Ashish Kumar Asthana
Ashutosh Rawat
Seemant Handa
Bhaskar Thakuria
Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
Indian Journal of Pathology and Microbiology
AmpC beta-lactamases
extended spectrum beta-lactamases
inhibitor based test
modified 3D test
title Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
title_full Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
title_fullStr Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
title_full_unstemmed Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
title_short Evaluation of phenotypic tests for the detection of AmpC beta-lactamase in clinical isolates of Escherichia coli
title_sort evaluation of phenotypic tests for the detection of ampc beta lactamase in clinical isolates of escherichia coli
topic AmpC beta-lactamases
extended spectrum beta-lactamases
inhibitor based test
modified 3D test
url http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=2;spage=135;epage=138;aulast=Handa
work_keys_str_mv AT deepikahanda evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli
AT anitapandey evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli
AT ashishkumarasthana evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli
AT ashutoshrawat evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli
AT seemanthanda evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli
AT bhaskarthakuria evaluationofphenotypictestsforthedetectionofampcbetalactamaseinclinicalisolatesofescherichiacoli